Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-11-21
2006-11-21
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S557000, C426S072000, C424S439000
Reexamination Certificate
active
07138431
ABSTRACT:
Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of Δ5desaturase, and optionally stearidonic acid or ω-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.
REFERENCES:
patent: 4154863 (1979-05-01), Kahn et al.
patent: 4309415 (1982-01-01), Horrobin
patent: 4386072 (1983-05-01), Horrobin et al.
patent: 4444755 (1984-04-01), Horrobin
patent: 4560514 (1985-12-01), Samuelsson et al.
patent: 4576758 (1986-03-01), Morris
patent: 4666701 (1987-05-01), Horrobin et al.
patent: 4758592 (1988-07-01), Horrobin et al.
patent: 4888326 (1989-12-01), Horrobin
patent: 4954638 (1990-09-01), Young et al.
patent: 4965075 (1990-10-01), Horrobin et al.
patent: 4977187 (1990-12-01), Horrobin
patent: 5141958 (1992-08-01), Crozier-Willi et al.
patent: 5158975 (1992-10-01), Guichardant et al.
patent: 5178873 (1993-01-01), Horrobin et al.
patent: 5223285 (1993-06-01), DeMichele et al.
patent: 5328691 (1994-07-01), Horrobin et al.
patent: 5336496 (1994-08-01), Akimoto et al.
patent: 5352700 (1994-10-01), Frithz et al.
patent: 5411988 (1995-05-01), Bockow et al.
patent: 5508307 (1996-04-01), Horrobin et al.
patent: 5516801 (1996-05-01), Horrobin et al.
patent: 5562913 (1996-10-01), Horrobin
patent: 5683898 (1997-11-01), Yazawa et al.
patent: 5734034 (1998-03-01), Jayasena et al.
patent: 0 598 365 (1994-05-01), None
patent: 0 598 365 (1994-05-01), None
patent: 0 711 503 (1996-05-01), None
patent: 0 713 653 (1996-05-01), None
patent: 782827 (1997-07-01), None
patent: WO 9602488 (1996-02-01), None
patent: WO 96/31457 (1996-10-01), None
patent: WO 97/21434 (1997-06-01), None
patent: WO 9816216 (1998-04-01), None
Obukowicz, et al., “Identification and Characterization of a Novel Δ6/Δ5 Fatty Acid Desaturase Inhibitor As a Potential Anti-Inflammatory Agent,” 55:1045-58, 1998.
Palombo, et al., “Metabolic Support: Cyclic vs Continuous Enternal Feeding With ω-3 and γ-Linolenic Fatty Acids: Effects on Modulation of Phospholipid Fatty Acids in Rat Lung and Liver Immune Cells,” Journal of Parenteral and Enternal Nutrition, 21(3):123-132, May 1996.
Dialog Search Patent Family printed Jun. 3, 1998.
Byars et al., “Black Currant Seed Oil as a Source Polyunsaturated Fatty Acids in the Treatment of Inflammatory Disease,” (Abstract) Biochem. Soc. Trans. 20(12), 139s, 1992.
Rothman et al., “Effects of Unsaturated Fatty Acids on Interleukin-1.Beta Production by Human Monocytes,” (Abstract) Cytokine, 9(12):1008-12, 1997.
International Search Report, PCT/US99/03120, Jun. 24, 1999.
Nasser et al.The Influence of Dietary Manipulation with n-3 and n-6 Fatty Acids on Liver and Plasma Phospholipid Fatty Acids in Rats.Lipids, vol. 21 (10), 1986, pp. 652-656.
Nasser et al.Response of Tissue Phospholipid Fatty Acid Composition to Dietary(n-6)and Replacement with Marine(n-3)and Saturated Fatty Acids in the Rat.Nutrition Research, vol. 6, 1986, pp. 1397-1409.
Takahashi et al.Effect of Different Ratios of Dietary N-6 and N-3 Fatty Acids on Fatty Acid Composition, Prostaglandin Formation and Platelet Aggregation in the Rat.Thrombosis Research, vol. 47, 1987, pp. 135-146.
Horrobin et al.Clinical Biochemistry of Essential Fatty Acids.Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine, 1990, pp. 21-53.
Huang et al.Modulation of Tissue Fatty Acid Composition, Prostaglandin Production and Cholesterol Levels by Dietary Manipulation of n-3 and n-6 Essential Fatty Acid Metabolites. Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine, 1990, pp. 127-144.
Zurler et al.Anti-Inflammatory Effects of γ-Linolenic Acid: Studies in Animals and in Cultured Cells. Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine, 1990, pp. 203-221.
Third party observations submitted by Reddie & Grose in European Application No. 99906992.5 (Feb. 14, 2002).
Kim Jennifer
Myers Bigel & Sibley Sajovec, PA
Padmanabhan Sreeni
Wake Forest University
LandOfFree
Dietary control of arachidonic acid metabolism does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dietary control of arachidonic acid metabolism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dietary control of arachidonic acid metabolism will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3690092